|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KRT1 |
Gene summary for KRT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KRT1 | Gene ID | 3848 |
| Gene name | keratin 1 | |
| Gene Alias | CK1 | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P04264 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3848 | KRT1 | CA_HPV_1 | Human | Cervix | CC | 3.31e-02 | -1.97e-01 | 0.0264 |
| 3848 | KRT1 | CA_HPV_2 | Human | Cervix | CC | 6.26e-03 | -2.17e-01 | 0.0391 |
| 3848 | KRT1 | CA_HPV_3 | Human | Cervix | CC | 1.43e-02 | 4.87e-01 | 0.0414 |
| 3848 | KRT1 | N_HPV_1 | Human | Cervix | N_HPV | 1.93e-06 | -2.46e-01 | 0.0079 |
| 3848 | KRT1 | N_HPV_2 | Human | Cervix | N_HPV | 1.75e-13 | 6.51e-01 | -0.0131 |
| 3848 | KRT1 | Tumor | Human | Cervix | CC | 2.98e-30 | 9.28e-01 | 0.1241 |
| 3848 | KRT1 | sample3 | Human | Cervix | CC | 3.84e-11 | 5.60e-01 | 0.1387 |
| 3848 | KRT1 | H2 | Human | Cervix | HSIL_HPV | 9.00e-07 | -2.45e-01 | 0.0632 |
| 3848 | KRT1 | T1 | Human | Cervix | CC | 3.40e-05 | -2.54e-01 | 0.0918 |
| 3848 | KRT1 | T3 | Human | Cervix | CC | 6.96e-16 | 6.31e-01 | 0.1389 |
| 3848 | KRT1 | P1_S1_AK | Human | Skin | AK | 1.36e-04 | 8.04e-02 | -0.3399 |
| 3848 | KRT1 | P2_S3_AK | Human | Skin | AK | 8.77e-11 | -1.52e-02 | -0.3287 |
| 3848 | KRT1 | P2_S4_SCCIS | Human | Skin | SCCIS | 5.46e-16 | -5.70e-01 | -0.3043 |
| 3848 | KRT1 | P3_S6_AK | Human | Skin | AK | 7.17e-32 | 8.98e-01 | -0.3256 |
| 3848 | KRT1 | P5_S10_cSCC | Human | Skin | cSCC | 1.73e-25 | -7.80e-01 | -0.299 |
| 3848 | KRT1 | P4_cSCC | Human | Skin | cSCC | 2.42e-08 | 1.09e+00 | -0.00290000000000005 |
| 3848 | KRT1 | P10_cSCC | Human | Skin | cSCC | 1.04e-07 | -5.05e-01 | 0.1017 |
| 3848 | KRT1 | cSCC_p1 | Human | Skin | cSCC | 5.72e-06 | 4.94e-01 | -0.1916 |
| 3848 | KRT1 | cSCC_p10 | Human | Skin | cSCC | 3.93e-10 | 3.70e-01 | -0.2095 |
| 3848 | KRT1 | cSCC_p11 | Human | Skin | cSCC | 1.58e-18 | 4.56e-01 | -0.2102 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003428418 | Prostate | BPH | response to monosaccharide | 61/3107 | 225/18723 | 4.34e-05 | 4.60e-04 | 61 |
| GO:00435886 | Prostate | BPH | skin development | 69/3107 | 263/18723 | 4.49e-05 | 4.73e-04 | 69 |
| GO:00607063 | Prostate | BPH | cell differentiation involved in embryonic placenta development | 13/3107 | 25/18723 | 5.04e-05 | 5.21e-04 | 13 |
| GO:19040196 | Prostate | BPH | epithelial cell apoptotic process | 37/3107 | 121/18723 | 9.71e-05 | 9.04e-04 | 37 |
| GO:00085448 | Prostate | BPH | epidermis development | 80/3107 | 324/18723 | 1.12e-04 | 1.02e-03 | 80 |
| GO:000974617 | Prostate | BPH | response to hexose | 58/3107 | 219/18723 | 1.33e-04 | 1.19e-03 | 58 |
| GO:007135616 | Prostate | BPH | cellular response to tumor necrosis factor | 60/3107 | 229/18723 | 1.42e-04 | 1.26e-03 | 60 |
| GO:00488636 | Prostate | BPH | stem cell differentiation | 55/3107 | 206/18723 | 1.56e-04 | 1.36e-03 | 55 |
| GO:00459279 | Prostate | BPH | positive regulation of growth | 66/3107 | 259/18723 | 1.64e-04 | 1.43e-03 | 66 |
| GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
| GO:00102127 | Prostate | BPH | response to ionizing radiation | 42/3107 | 148/18723 | 2.20e-04 | 1.78e-03 | 42 |
| GO:005087817 | Prostate | BPH | regulation of body fluid levels | 89/3107 | 379/18723 | 3.08e-04 | 2.37e-03 | 89 |
| GO:00099138 | Prostate | BPH | epidermal cell differentiation | 52/3107 | 202/18723 | 5.95e-04 | 4.11e-03 | 52 |
| GO:00426926 | Prostate | BPH | muscle cell differentiation | 88/3107 | 384/18723 | 7.59e-04 | 5.01e-03 | 88 |
| GO:00302165 | Prostate | BPH | keratinocyte differentiation | 38/3107 | 139/18723 | 9.35e-04 | 5.92e-03 | 38 |
| GO:00068937 | Prostate | BPH | Golgi to plasma membrane transport | 19/3107 | 60/18723 | 2.94e-03 | 1.54e-02 | 19 |
| GO:00619517 | Prostate | BPH | establishment of protein localization to plasma membrane | 19/3107 | 60/18723 | 2.94e-03 | 1.54e-02 | 19 |
| GO:00456824 | Prostate | BPH | regulation of epidermis development | 20/3107 | 65/18723 | 3.36e-03 | 1.73e-02 | 20 |
| GO:00430017 | Prostate | BPH | Golgi to plasma membrane protein transport | 14/3107 | 40/18723 | 3.68e-03 | 1.85e-02 | 14 |
| GO:00614363 | Prostate | BPH | establishment of skin barrier | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KRT1 | SNV | Missense_Mutation | novel | c.62C>T | p.Ser21Phe | p.S21F | P04264 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KRT1 | SNV | Missense_Mutation | novel | c.1807N>A | p.Gly603Ser | p.G603S | P04264 | protein_coding | tolerated_low_confidence(0.56) | benign(0.006) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| KRT1 | SNV | Missense_Mutation | rs771587972 | c.751N>T | p.Arg251Trp | p.R251W | P04264 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KRT1 | SNV | Missense_Mutation | c.1027N>T | p.Arg343Cys | p.R343C | P04264 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
| KRT1 | SNV | Missense_Mutation | c.1307C>T | p.Ala436Val | p.A436V | P04264 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KRT1 | deletion | Frame_Shift_Del | novel | c.402delN | p.Phe134LeufsTer43 | p.F134Lfs*43 | P04264 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| KRT1 | SNV | Missense_Mutation | c.655N>A | p.Asp219Asn | p.D219N | P04264 | protein_coding | tolerated(0.38) | benign(0.066) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| KRT1 | SNV | Missense_Mutation | c.811N>C | p.Glu271Gln | p.E271Q | P04264 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| KRT1 | SNV | Missense_Mutation | novel | c.1811C>T | p.Ser604Phe | p.S604F | P04264 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.554) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KRT1 | SNV | Missense_Mutation | novel | c.971N>G | p.Ser324Cys | p.S324C | P04264 | protein_coding | deleterious(0.02) | probably_damaging(0.923) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |